Skip to main
IRD
IRD logo

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics Inc. has demonstrated promising initial results in clinical trials for its gene therapies targeting inherited retinal diseases, specifically showing significant gains in visual acuity and sensitivity across various assessments in patients. The company's pipeline, particularly the APX3330 therapy for non-proliferative diabetic retinopathy, aligns well with the substantial market opportunity of approximately 10 million patients in the U.S., indicating strong commercial potential. Additionally, the anticipated data rollout for pediatric patients starting in Q3 2025, coupled with positive trends observed in older patient cohorts, provides a solid basis for future growth and investment in Opus Genetics's innovative therapeutic offerings.

Bears say

Opus Genetics Inc. faces significant risks that contribute to a negative outlook on its stock, primarily related to the commercial viability of its product pipeline. The potential failure of its gene therapies and other treatments to meet projected peak revenue targets could hinder financial performance, particularly given the competitive landscape and uncertain market dynamics. Additionally, reliance on securing adequate capital to sustain operations and advance program development raises further concerns regarding the company's financial stability and long-term success.

Opus Genetics (IRD) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Opus Genetics (IRD) has a Strong Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.